Subscribe
eye-istock-489756064-mark_kuiken-
Mark_Kuiken / iStockphoto.com
15 August 2018Asia-Pacific

Astellas boosts ocular pipeline with gene therapy acquisition

Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Astellas doubles down on gene therapy with $3bn Audentes deal
5 December 2019   Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.
Asia-Pacific
Astellas-backed Crescendo pairs up with Zai Lab in licensing deal
31 May 2018   UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Americas
Astellas Pharma expands portfolio by acquiring Universal Cells
16 February 2018   Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Astellas doubles down on gene therapy with $3bn Audentes deal
5 December 2019   Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.
Asia-Pacific
Astellas-backed Crescendo pairs up with Zai Lab in licensing deal
31 May 2018   UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Americas
Astellas Pharma expands portfolio by acquiring Universal Cells
16 February 2018   Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.

More on this story

Americas
Astellas doubles down on gene therapy with $3bn Audentes deal
5 December 2019   Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.
Asia-Pacific
Astellas-backed Crescendo pairs up with Zai Lab in licensing deal
31 May 2018   UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
Americas
Astellas Pharma expands portfolio by acquiring Universal Cells
16 February 2018   Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB